Related references
Note: Only part of the references are listed.IL-1 Family Members in Cancer; Two Sides to Every Story
Kevin J. Baker et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Samra Turajlic et al.
CELL (2018)
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Thomas J. Mitchell et al.
CELL (2018)
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Samra Turajlic et al.
CELL (2018)
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
Francesc Castro-Giner et al.
DIAGNOSTICS (2018)
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid
Makoto Tahara et al.
EUROPEAN JOURNAL OF CANCER (2017)
Heterogeneity in renal cell carcinoma
Alp Tuna Beksac et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
Masahiro Matsuki et al.
CANCER SCIENCE (2017)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger et al.
CLINICAL CANCER RESEARCH (2016)
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2016)
TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway
Guohe Song et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment
Maria E. Cabanillas et al.
CANCER (2015)
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Liem M. Phan et al.
CANCER RESEARCH (2015)
Cellular and molecular effects of the mTOR inhibitor everolimus
Uttara Saran et al.
CLINICAL SCIENCE (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-na < ve patients with metastatic renal cell carcinoma
Charles S. Harmon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
Robert J. Motzer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
A. J. Zurita et al.
ANNALS OF ONCOLOGY (2012)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Roberta Mazzieri et al.
CANCER CELL (2011)
Pro- and anti-inflammatory control of M-CSF-mediated macrophage differentiation
Anna Popova et al.
IMMUNOBIOLOGY (2011)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tissue Biomarkers in Renal Cell Carcinoma: Issues and Solutions
Arianna Di Napoli et al.
CANCER (2009)
Fibroblast Hepatocyte Growth Factor Promotes Invasion of Human Mammary Ductal Carcinoma In situ
Christopher Jedeszko et al.
CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells
Naoki Oka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E. DePrimo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma
R. Zhang et al.
GENE THERAPY (2006)
Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain
YQ Zhu et al.
STROKE (2005)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
